0

When Eosinophils Attack

Click below to access your content. Once you have successfully completed this course your certificate will become available at the top of this page and on your My Certificates page.

Course Details

Credit/contact hours: .5
Estimated time to complete: 30 minutes
Publication Date: March 8, 2018
Expiration date: March 7, 2021
Reviewed:

Description:

This interesting case involves a patient with cardiogenic shock due to an unusual form of cardiomyopathy. This diagnosis is frequently missed as it is often not even considered. Our patient was treated with an LVAD and histopathologic examination of the myocardium plug sampled during surgery led to the diagnosis. The patient was treated with both left and right ventricular support devices (LVAD, RVAD) and survived through hospital discharge.

You Will Learn

  • To describe patient characteristics that are consistent with a diagnosis of eosinophilic cardiomyopathy
  • To outline the clinical features of the disease
  • To describe the natural history and potential for treatment of eosinophilic cardiomyopathy

Method and medium:

Learners participate in the interactive learning modules by correctly answering multiple choice questions dispersed throughout. Learners will be prompted to try again if a question is answered incorrectly.The course will open in a new tab - to exit the course, simply close that tab.

Lawrence W Gimple, MD

Dr. Gimple is an attending cardiologist at the University of Virginia Health System with a sub-specialty in interventional cardiology.  He serves as the Director of Clinical Cardiology at the University of Virginia Health System with clinical interests in coronary artery disease, coronary stenting, and heart attack.

DISCLOSURE: This individual reports no relevant financial relationships with commercial entities.

Ryan Connolly, MD

Dr. Ryan Connolly is a Fellow in Cardiovascular Disease at the University of Virginia Health System.

DISCLOSURE: This individual reports no relevant financial relationships with commercial entities.

Please rate this


 4.4/5 (5)